Filing Flows › Protalix BioTherapeutics (PLX) › Q4 2024
Protalix BioTherapeutics (PLX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 17, 2025
Protalix BioTherapeutics (PLX) reported revenue of $18.2M for the fourth quarter 2024 (Q4 2024), +74% from a year earlier and +1% from the quarter before. Operating margin was 39.6%, net earnings $6.5M (35.6% of revenue).
Protalix BioTherapeutics, Q4 2024: revenue $18.2M (+74% year over year), operating margin 39.6%, net earnings $6.5M, operating cash flow $4.0M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $18.2M | +1% | +74% |
| Operating profit | $7.2M | +81% | — |
| Net earnings | $6.5M | +101% | — |
| Operating cash flow | $4.0M | -3% | +11% |
| Free cash flow | $3.6M | -11% | +7% |
What changed
Revenue was $18.2M in Q4 2024, up 74% year over year and up 1% from the previous quarter. GOODS was the largest line at 100% of revenue.
Operating profit was $7.2M, a 39.6% margin (up 93.1 points year over year). Total costs fell 32% while revenue rose 74%. The fastest-growing cost line was Research & development (+33%). Net earnings were $6.5M. The effective tax rate was 11.2%.
Operating cash flow was $4.0M (up 11% year over year), 61% of net earnings. Non-cash charges added back $334K of depreciation and $654K of share-based compensation. Working capital and other items used $3.5M. Capital expenditures of $425K left free cash flow of $3.6M.
Questions
What was Protalix BioTherapeutics' revenue in the fourth quarter 2024?
Protalix BioTherapeutics (PLX) reported revenue of $18.2M for the fourth quarter 2024 (Q4 2024), +74% from a year earlier and +1% from the quarter before.
Was Protalix BioTherapeutics profitable in the fourth quarter 2024?
Operating profit was $7.2M (39.6% of revenue) and net earnings $6.5M.